Review of recombinant human deoxyribonuclease (rhDNase) in the management of patients with cystic fibrosis

Tacjana Pressler

CF Centre, Dept. of Pediatrics, Rigshospitalet, University of Copenhagen Denmark

Abstract: The most important problem in cystic fibrosis (CF) lung disease is chronic airway inflammation and infection, which starts early in life. To prevent severe lung damage, it is important to mobilize as much sputum as possible from the lung on a daily basis. RhDNase is an enzyme that breaks down DNA strands in airway secretions, hydrolyzes the DNA present in sputum/mucus of CF patients, reducing viscosity in the lungs and promoting secretion clearance. Several well performed trials have proven its efficacy in young CF patients with mild disease as well as in older patients with more advanced lung disease. Daily inhalation of this agent slows down lung function decline and decreases the frequency of respiratory exacerbations. The drug is well tolerated by most patients independent of the severity of lung disease.

Keywords: cystic fibrosis, lung disease, recombinant human deoxyribonuclease